IVAC MUTANOME Phase I Clinical Trial

Inclusion Criteria: * Malignant Melanoma, resectable stage IIIA-C and IV (AJCC 2009 melanoma classification) * Patients with unresectable Malignant Melanoma stage IIIA-C in complete remission, partial remission or stable disease after treatment with vemurafenib or patients with slow progressive disease. * Malignant Melanoma, unresectable stage IV (AJCC 2009 melanoma classification) in complete remission, partial remission or stable disease after treatment with vemurafenib * All lines of treatment for malignant melanoma are accepted. * First line therapy for subjects not eligible or declining other first line therapies after all available treatment options have been transparently disclosed (to be documented in patient medical record). * ≥ 18 years of age * Written informed consent * ECOG performance status (PS) 0-1 (appendix G) * Life expectancy \> 6 months * WBC ≥ 3x109/L * Haemoglobin ≥ 10 g/dl * Platelet count ≥ 100,000/mm³ * LDH level \< 2.0 x ULN * Negative pregnancy test (measured by β-HCG) for females which are childbearing potential * Suitable lymph nodes for injection using ultrasound guidance Exclusion Criteria: * Pregnancy or breastfeeding * Primary ocular melanoma * History (\< 5 years) of a second malignancy other than squamous or basal cell carcinoma, non-active prostate cancer or cervical carcinoma in situ * Brain metastases * Known or symptomatic pleural effusions and/or ascites * Known hypersensitivity to the active substance or to any of the excipients * A serious local infection (e.g. cellulitis, abscess) or systemic infection (e.g. pneumonia, septicemia) which requires systemic antibiotic treatment within 2 weeks prior to the first dose of study medication * Positive test for acute or chronic active hepatitis B or C infection, acute EBV or acute CMV injection * Clinically relevant autoimmune disease * Systemic immune suppression: * HIV disease * Use of chronic oral or systemic steroid medication (topical or inhalational steroids are permitted) * Other clinical relevant systemic immune suppression * Symptomatic congestive heart failure (NYHA 3 or 4) * Unstable angina pectoris * Radiotherapy within two weeks, myelosuppressive chemotherapy, ipilimumab and major surgery within 4 weeks/28 days before the first treatment. Interferon and approved BRAF inhibitors will be allowed as concurrent treatment. * Any investigational drug within 4 weeks/28 days or 5 half-lives depending on what gives the longer range before the first treatment of this study * Minor surgery within 14 days before the first treatment of this study * Fertile males and females who are unwilling to use a highly effective method of birth control (less than 1% per year, e.g. condom with spermicide, diaphragm with spermicide, birth control pills, injections, patches or intrauterine device) during study treatment and 28 days after the last dose of study treatment * Presence of a serious concurrent illness or other condition (e.g. psychological, family, sociological, or geographical circumstances) that does not permit adequate follow-up and compliance with the protocol